Landmark GI Study Results from over 4,600 patients
Released
Released
Announcement PDF
ASX Announcement
14 May 2025
Landmark GI Study Results from over 4,600 patients
Results at a glance:
•
•
71.4% of MetaXplore™ reports from 4,616
patients identified actionable results
o
41.9% tested positive for abnormal
microbiome markers linked to
gastrointestinal health
o
9.9% tested positive for gastrointestinal
markers, including inflammation,
pancreatic insufficiency, or blood in stool
o
19.6% of reports tested positive for
multiple markers (microbiome and
gastrointestinal)
65% of patients reported health
improvements following clinician-directed
recommendations informed by MetaXplore
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today
announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for
the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating,
constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address
underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings,
such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted
treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported
improvement of symptoms after their care was guided by the test results.
These results highlight the clinical value of MetaXplore test results in advancing outcomes for patients with chronic lower
gastrointestinal disorders, highlighting the potential to reshape clinical management of these conditions and set a new
standard of care. An in-depth analysis of billing and claims data for MetaXplore target patient populations, has estimated an
addressable population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia
MetaXplore™ Identifies Actionable Results in the Majority of Cases
Analysis conducted by Microba of 4,616 MetaXploreTM GI Plus patients test results from Australia revealed that 71.4% (3,295) of
reports identified actionable results.
•
41.9% (1,932) of reports showed abnormal microbiome markers linked to gastrointestinal health, including 7%
that were positive for a pathogen species that can cause GI infection. These abnormal microbiome markers can be
addressed via evidence-based targeted nutritional or lifestyle changes, or antimicrobial therapy (antibiotics)
when a pathogen is identified.
•
9.9% (459) of reports tested positive for a gastrointestinal marker (e.g. inflammation, pancreatic insufficiency, or faecal
occult blood), prompting further diagnostic workup and supporting management of conditions such as
inflammatory bowel disease (IBD), colorectal cancer, or pancreatic insufficiency via pharmacological treatment
.
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
Visit ir.microba.com/welcome for Microba’s interactive Investor Hub
Microba Life Sciences Ltd ABN 82 617 096 652 | Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
ASX Announcement
14 May 2025
including biologics
•
19.6% (904) of reports tested positive for multiple markers (microbiome and gastrointestinal), addressed via a
personalised mix of pharmacological, nutritional and lifestyle modification strategies
These results demonstrate how the MetaXplore test provides critical new insights to enable clinicians to apply personalised, multidimensional treatment plans to support the clinical management of patients with chronic and functional lower gastrointestinal
disorders. In cases where no significant findings were identified, the results can help clinicians to rule out and narrow potential
causes of the patients’ gastrointestinal symptoms, and may suggest psychological or neurological contributors to symptoms which
empower additional clinical pathways. This study is ongoing, supports the integration of MetaXplore testing into standard care
protocols, and is expected to be published in peer-reviewed journals.
MetaXplore™ Patients Report Measurable Health Benefits
A separate study of 84 patients by Microba who received MetaXplore-guided care found that 65.5% reported health
improvements after following their clinician’s recommendations:
•
22.6% reported significant improvement
•
42.9% noticed some improvement
These preliminary results highlight how the MetaXplore test results and personalised, targeted interventions improve patient
outcomes. This initial patient survey data demonstrates the relationship between MetaXplore positive test results and improved
patient outcomes, supporting the clinical impact Microba is seeing with clinicians and patients, and setting up for larger planned
studies measuring patient outcomes.
Associate Professor Graham Radford-Smith, a leading gastroenterologist and expert in functional GI disorders, is currently working
with Microba on a clinical utility study of MetaXploreTM in his practice. He commented:
“MetaXplore is a powerful addition to the diagnostic toolbox for patients with persistent gastrointestinal symptoms. It enables me
to objectively identify microbiome dysbiosis, evaluate dietary quality, and direct patients toward evidence-based nutritional
strategies. Importantly, it helps differentiate patients with normal GI and microbial profiles who may benefit from psychological
support rather than further invasive testing or pharmacological escalation.”
Addressable market of over 82 million patients with lower gastrointestinal symptoms
An in-depth analysis of billing and claims data for MetaXplore target patient populations, estimated an addressable
population of 82.2 million patients across US, Germany, Italy, Spain, France, United Kingdom and Australia 1. This population
consists of patients with chronic diarrhoea or non-specific abdominal symptoms such as pain, bloating and constipation,
including patients characterised with Irritable Bowel Syndrome (IBS) or diagnosed with Inflammatory Bowel Disease (IBD).
The current standard of care for these patients is leading to an estimated 50% of patients not getting a resolution to their
symptoms 2, necessitating a radical advancement in the tools available to support these patients and improve outcomes.
MetaXploreTM is supporting clinicians to manage and improve outcomes for these patients through a comprehensive test that
can:
•
Assess structural and functional abnormalities in the microbiome
1
Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims analysis for target
patient populations, extrapolated Private and Medicaid numbers, populations and prevalence adjusted for key global markets spanning outside of US
including Germany, Italy, Spain, France, United Kingdom and Australia.
2
Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family
Physician, 44(9), 621-623
.
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
Visit ir.microba.com/welcome for Microba’s interactive Investor Hub
Microba Life Sciences Ltd ABN 82 617 096 652 | Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
ASX Announcement
14 May 2025
•
Detect overlooked harmful gut bacteria (pathogens), inflammatory or insufficiency markers
•
Identify evidence based, personalised pharmacological, nutritional and lifestyle modification strategies
•
Support patient motivation and adherence to pharmacological, nutritional and lifestyle modifications
•
May support identification of cases where mental health support may be appropriate
As the burden of chronic digestive disorders continues to grow, MetaXplore offers a scalable, evidence-based new solution
to evaluate and clinically manage GI dysfunction.
This announcement has been authorised for release by the Chair and Chief Executive Officer.
For further information, please contact:
Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com
https://ir.microba.com/welcome
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology
for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for
major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers.
Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the
microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com
View this announcement on our Investor Hub: https://ir.microba.com/link/NPwopP
.
JOIN MICROBA’S INTERACTIVE INVESTOR HUB
Visit ir.microba.com/welcome for Microba’s interactive Investor Hub
Microba Life Sciences Ltd ABN 82 617 096 652 | Level 10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621
Share your feedback
Discover